Yuval Horn, Shimrit Roznek and Yael Bar Hillel represented Metabomed Ltd. in its Asset Purchase Agreement with EpiVario Inc., for the sale of Metabomed’s small molecule acetyl co-A synthetase-2 inhibitor portfolio.
January 24, 2024
Congratulations to our client, Biosight Ltd. on completing the merger with Ayala Pharmaceuticals, Inc. Yuval Horn, Assaf Unger and Ana Eiskov represented Biosight, together with Mayan Katz of Goodwin.
October 22, 2023
Congratulations to our client, Vascular Biogenics Ltd. (Nasdaq: VBLT) on completing the merger with Notable Labs and the sale of its IP assets. VBL was represented by Horn & Co. (Yuval Horn, Shimrit Roznek, Roy Ribon, Yael Bar-Hillel and Shai Perel) and by Goodwin.
October 19, 2023
Yuval Horn, Assaf Unger, Ana Eiskov and Shiran Glantz represent Biosight Ltd. in the merger agreement with Ayala Pharmaceuticals, Inc.
July 31, 2023
Yuval Horn, Assaf Unger, Ana Eiskov and Revital Guttman represented our client, INX, in its investment and collaboration transactions with Republic
June 25, 2023
Keren Kanir, Yuval Horn and Danielle Wassner represented Scopio Labs in its collaboration agreement with Siemens Healthineers to Distribute Full-Field Digital Cell Morphology Technology
May 10, 2023
Uri Dotan and Shira Brami represented Vidac Pharma Ltd. in the registration of Its securities on the Hamburg Stock Exchange
April 5, 2023
Yuval Horn Co Chaired the IBA 6th M&A in the Tech Sector Conference on March 23-24, 2023.
March 25, 2023
Tal Gazanda represented ART MEDICAL in a strategic collaboration agreement with Teva Pharmaceuticals (TEVA).
March 19, 2023
Yuval Horn, Paz Abercohen, Ana Eiskov, Shiran Glantz and Shai Perel represent VBL in the merger with Notable.
February 23, 2023